Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348439 | 0.89 | CRBN (0.46) | CRBNDDB1PDCD1CD274JAK2 | |
| SCHEMBL29348386 | 0.89 | CRBN (0.46) | CRBNDDB1PDCD1CD274JAK2 | |
| SCHEMBL29348437 | 0.89 | CRBN (0.46) | CRBNDDB1PDCD1CD274JAK2 | |
| SCHEMBL31068109 | 0.89 | CRBN (0.46) | CRBNDDB1PDCD1CD274JAK2 | |
| SCHEMBL31068149 | 0.89 | CRBN (0.46) | CRBNDDB1PDCD1CD274JAK2 | |
| SCHEMBL29348288 | 0.85 | CRBN (0.44) | CRBNDDB1JAK2ALOX5AP | |
| SCHEMBL29348677 | 0.84 | CRBN (0.44) | CRBNDDB1PDCD1CD274JAK2 | |
| SCHEMBL31068135 | 0.84 | CRBN (0.44) | CRBNDDB1PDCD1CD274JAK2 | |
| SCHEMBL31068294 | 0.82 | DDB1 (0.43) | CRBNDDB1PDCD1CD274JAK2 | |
| SCHEMBL29348475 | 0.82 | DDB1 (0.43) | CRBNDDB1PDCD1CD274JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | CRBN 144/4885DDB1 1125/4885PDCD1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.